Blood Advances

Scope & Guideline

Elevating Hematology Through Cutting-Edge Research

Introduction

Welcome to your portal for understanding Blood Advances, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN2473-9529
PublisherELSEVIER
Support Open AccessYes
CountryUnited States
TypeJournal
Convergefrom 2017 to 2024
AbbreviationBLOOD ADV / Blood Adv.
Frequency24 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressRADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS

Aims and Scopes

Blood Advances is a leading journal focused on publishing high-quality research in the field of hematology, emphasizing clinical and translational studies. The journal aims to advance the understanding and treatment of blood disorders, with a commitment to improving patient care through innovative research and practice.
  1. Clinical Hematology:
    The journal prioritizes clinical studies that address the diagnosis, treatment, and management of hematologic disorders, including leukemia, lymphoma, myeloma, and bleeding disorders.
  2. Translational Research:
    Research that bridges laboratory findings with clinical applications is a core focus, facilitating the development of new therapies and improving existing treatment protocols.
  3. Innovative Therapies:
    The journal highlights advancements in novel therapies, including CAR T-cell therapy, gene therapy, and immunotherapy, showcasing their efficacy and safety in various hematologic conditions.
  4. Health Equity and Disparities:
    Recent publications emphasize the importance of addressing health disparities in hematologic diseases, focusing on demographic factors such as race, ethnicity, and socioeconomic status.
  5. Patient-Centered Approaches:
    Research that explores patient-reported outcomes and quality of life in patients with blood disorders is increasingly emphasized, reflecting a commitment to holistic patient care.
  6. Molecular and Genetic Insights:
    The journal publishes studies that investigate the molecular and genetic underpinnings of hematologic diseases, contributing to personalized medicine and targeted therapies.
Blood Advances has seen a significant evolution in research themes, with many emerging trends reflecting the rapid advancement of technology and therapeutic strategies in hematology. This includes a growing focus on patient-centered care and innovative treatment modalities.
  1. CAR T-cell Therapy:
    Research on CAR T-cell therapy continues to expand, with numerous studies investigating its efficacy across various hematologic malignancies, reflecting its growing role as a frontline treatment option.
  2. Gene Therapy:
    There is an increasing emphasis on gene therapy approaches, particularly for conditions like sickle cell disease and hemophilia, showcasing innovative strategies to correct genetic defects.
  3. Immune Profiling and Biomarkers:
    Emerging studies are focusing on immune profiling and the identification of biomarkers for predicting treatment responses and outcomes, which are essential for personalized medicine.
  4. Health Disparities and Access to Care:
    Research addressing health disparities, particularly pertaining to access to care and treatment outcomes in diverse populations, is gaining traction, reflecting a broader commitment to health equity.
  5. Longitudinal Patient-Reported Outcomes:
    The trend towards incorporating patient-reported outcomes in clinical studies is on the rise, emphasizing the importance of understanding the patient experience and quality of life in hematology.
  6. Utilization of Artificial Intelligence and Machine Learning:
    The application of AI and machine learning in hematology research is emerging, particularly in predictive modeling and personalized treatment strategies.

Declining or Waning

While Blood Advances continues to thrive in numerous research areas, some topics have seen a decline in focus or frequency of publication. This may reflect evolving priorities in hematological research, as well as the emergence of new areas of interest.
  1. Traditional Chemotherapy Approaches:
    As newer therapies such as targeted agents and immunotherapies gain traction, traditional chemotherapy studies are becoming less prominent, suggesting a shift towards more innovative treatment strategies.
  2. Epidemiological Studies:
    There has been a noticeable decrease in the number of epidemiological studies exploring the incidence and prevalence of hematologic disorders, possibly due to a growing focus on personalized and targeted therapies.
  3. Basic Science Research:
    The journal appears to be publishing fewer basic science studies that do not have immediate clinical implications, as there is a stronger emphasis on translational research that directly impacts patient care.
  4. Longitudinal Studies on Established Treatments:
    Fewer studies are being published that focus on long-term outcomes of established treatments, indicating a potential waning interest in revisiting older treatment modalities in favor of exploring novel therapies.

Similar Journals

ANNALS OF HEMATOLOGY

Elevating knowledge with impactful research and reviews.
Publisher: SPRINGERISSN: 0939-5555Frequency: 12 issues/year

ANNALS OF HEMATOLOGY, published by Springer in Germany, stands as a premier platform for advancing knowledge in the field of hematology and medicine at large. With a significant impact factor and recognized rankings—Q2 in Hematology and Q1 in Medicine (miscellaneous) as of 2023—this journal is pivotal for researchers, clinicians, and students who are keen on exploring the latest developments in blood disorders, treatments, and innovative methodologies. Its broad scope encompasses original research, reviews, and discussions that aim to foster interdisciplinary dialogue, ensuring that the latest findings and theories are accessible to the scientific community. Although not an open-access journal, its rigorous peer-review process guarantees high-quality contributions, thereby solidifying its reputation as a vital resource in the hematological field. Founded in 1991, the ANNALS OF HEMATOLOGY continues to evolve, converging invaluable insights from both basic and clinical research until 2024. For those dedicated to improving patient outcomes and advancing hematological science, this journal remains an essential reference.

LEUKEMIA & LYMPHOMA

Bridging research and clinical practice in blood cancers.
Publisher: TAYLOR & FRANCIS LTDISSN: 1042-8194Frequency: 12 issues/year

LEUKEMIA & LYMPHOMA is a prestigious peer-reviewed journal published by Taylor & Francis Ltd, focusing on vital research in the fields of hematology, oncology, and cancer research. With an ISSN of 1042-8194 and an E-ISSN of 1029-2403, this journal is recognized for its high-quality and impactful contributions to understanding blood cancers, with a notable impact factor reflective of its influence. Since its inception in 1989, LEUKEMIA & LYMPHOMA has continuously provided a platform for researchers and professionals to disseminate their findings, fostering advancements in diagnostic, therapeutic, and clinical strategies related to leukemias and lymphomas. The journal ranks in the Q2 category for both Hematology and Oncology research categories as of 2023, underscoring its commitment to excellence. The journal is based in the United Kingdom and serves a global audience, making it an essential resource for those dedicated to improving outcomes for patients with hematological malignancies.

Cancer Discovery

Uncovering Innovations in Cancer Biology
Publisher: AMER ASSOC CANCER RESEARCHISSN: 2159-8274Frequency: 12 issues/year

Cancer Discovery, published by the American Association for Cancer Research, stands as a vital resource in the oncological research community, renowned for its commitment to disseminating groundbreaking studies and innovative findings in cancer biology, prevention, diagnostics, and treatment. With a significant impact factor reflecting its esteemed position, this journal facilitates open discussions and collaborations, striving to bridge the gap between experimental and clinical research. The journal, which has been active since 2011, is classified as a Q1 publication in 2023, underscoring its influence and authority in the realm of Oncology. By providing a platform for rigorous peer-reviewed articles, Cancer Discovery aims to advance our understanding of cancer and enhance therapeutic strategies, making it an indispensable tool for researchers, professionals, and students eager to stay at the forefront of cancer research.

Journal of Blood Medicine

Unlocking Potential: Transforming Knowledge into Practice in Blood Medicine
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-2736Frequency: 1 issue/year

The Journal of Blood Medicine, published by DOVE MEDICAL PRESS LTD, stands as a vital resource in the field of hematology, focusing on the latest research developments and clinical advancements in blood medicine. With an impact factor reflective of its growing relevance, this open-access journal has been delivering quality scholarly work since 2010, ensuring that critical research is readily available to the global scientific community. The journal operates under an open-access model, further enhancing its dissemination and accessibility to researchers, professionals, and students alike. In the 2023 rankings, it secured a Q3 category status within hematology and achieved a commendable 76th rank out of 137 in Scopus listings, indicating its commitment to quality and innovation in this specialized area. Located in New Zealand, the journal's diverse topics encompass clinical research, treatment modalities, and emerging therapies, contributing significant insights vital for shaping future advancements in blood medicine.

Indian Journal of Hematology and Blood Transfusion

Fostering Collaboration in Hematology and Transfusion Medicine
Publisher: SPRINGER INDIAISSN: 0971-4502Frequency: 4 issues/year

Indian Journal of Hematology and Blood Transfusion, published by SPRINGER INDIA, serves as a leading platform for disseminating original research, reviews, and case studies in the field of hematology. With an ISSN of 0971-4502 and E-ISSN 0974-0449, this journal has been instrumental in advancing knowledge from 2000 to 2024, providing insights into critical issues surrounding blood disorders and transfusion practices. Currently ranked in the Q3 category for Hematology for 2023, it reflects a commitment to high-quality scientific content amidst a competitive landscape where it ranks 97/137 in Scopus for Medicine - Hematology, placing it in the 29th percentile of its peers. The journal primarily addresses a diverse readership, including researchers, healthcare professionals, and students, aiming to foster innovation and collaboration within the field. Although it operates under a subscription model, access options for individual articles and institutional subscriptions ensure that valuable research is disseminated widely to enhance medical practice and education in hematology.

Lancet Haematology

Elevating patient care with groundbreaking discoveries.
Publisher: ELSEVIER SCI LTDISSN: 2352-3026Frequency: 12 issues/year

Lancet Haematology, published by Elsevier Science Ltd in the United Kingdom, is a premier peer-reviewed journal dedicated to advancing the field of hematology. With an impressive impact factor and listed in the Q1 category in hematology for 2023, this journal ranks #4 out of 137 in the Scopus database, boasting a 97th percentile indicating its influential role in disseminating high-quality research. Since its establishment in 2014, Lancet Haematology has provided a vital platform for researchers and clinicians to share groundbreaking studies, innovative treatment approaches, and novel therapeutic discoveries relevant to various hematological disorders. The journal does not operate under an open access model, but it offers multiple access options to facilitate engagement with its content. By bridging clinical practice and cutting-edge research, Lancet Haematology aims to foster the advancement of knowledge and improve patient outcomes in hematology, making it an essential read for professionals, researchers, and students alike.

TRANSFUSION MEDICINE AND HEMOTHERAPY

Advancing transfusion science for better patient outcomes.
Publisher: KARGERISSN: 1660-3796Frequency: 6 issues/year

TRANSFUSION MEDICINE AND HEMOTHERAPY, published by KARGER, is a prominent journal dedicated to advancing the fields of hematology and transfusion medicine. With an ISSN of 1660-3796 and E-ISSN 1660-3818, this esteemed journal has been a valuable resource for researchers and clinicians since its inception in 1973, with significant publication phases continuing into 2024. It currently holds a Q2 ranking in Hematology and a Q3 ranking in Immunology and Allergy, reflecting its impact and relevance in these critical fields. The journal features original articles, reviews, and clinical studies, presenting cutting-edge research that aids in the development of effective therapies and enhances patient care. Open access options are available, ensuring that crucial findings are accessible to a broad audience. As an important platform for dialogue and advancement in transfusion science, TRANSFUSION MEDICINE AND HEMOTHERAPY supports the global health community's efforts to improve treatment outcomes and foster innovation in medical practices.

SEMINARS IN HEMATOLOGY

Advancing Hematology Through Insightful Research.
Publisher: W B SAUNDERS CO-ELSEVIER INCISSN: 0037-1963Frequency: 4 issues/year

SEMINARS IN HEMATOLOGY, published by W B SAUNDERS CO-ELSEVIER INC, stands as a premier academic journal dedicated to the field of hematology. Established in 1964, this journal has built a robust reputation over its nearly six-decade history, now recognized as a Q1 journal in Hematology with an impressive impact factor reflective of its high relevance and citation frequency within the academic community. Residents and scholars can access meticulously curated articles that address innovative research, clinical practices, and advancements in the understanding of blood disorders and treatment methodologies. The journal, ranked #36 out of 137 in the Scopus Medicine Hematology category, showcases cutting-edge research, ensuring its contributions are crucial for professionals, researchers, and students striving to stay at the forefront of the hematology field. Although not an Open Access journal, SEMINARS IN HEMATOLOGY continues to unite a global audience dedicated to advancing the science and clinical practices in hematology.

HAEMOPHILIA

Pioneering insights in hematology and genetics.
Publisher: WILEYISSN: 1351-8216Frequency: 6 issues/year

HAEMOPHILIA is a leading peer-reviewed journal published by Wiley, dedicated to advancing research and clinical practices in the fields of hematology and genetics. With an impressive Impact Factor and recognition within the Q1 category for Genetics (clinical), Hematology, and Medicine (miscellaneous), this journal presents a unique platform for the dissemination of high-quality research from 1995 to the present. Researchers in these dynamic fields will find invaluable insights through original articles, systematic reviews, and clinical trials, all aimed at improving therapeutic strategies and patient outcomes. Although it operates on a subscription basis, HAEMOPHILIA's commitment to excellence is reflected in its Scopus rankings, where it stands in the 74th percentile for hematology and the 71st percentile for clinical genetics. As an essential resource for academics, healthcare professionals, and students, HAEMOPHILIA plays a pivotal role in fostering innovation and collaboration within the global medical community.

BLOOD

Advancing the Science of Hematology.
Publisher: AMER SOC HEMATOLOGYISSN: 0006-4971Frequency: 52 issues/year

BLOOD, published by the American Society of Hematology, is a premier peer-reviewed journal in the fields of Biochemistry, Cell Biology, Hematology, and Immunology. With an impressive impact factor and ranking in the top quartiles (Q1) across multiple disciplines, BLOOD is essential reading for researchers and professionals seeking to stay updated on the latest advancements in hematology and related fields. The journal has been a cornerstone of hematological research since its inception in 1946, providing a platform for rigorous scientific inquiry and discourse. Its commitment to publishing high-quality original research, comprehensive reviews, and insightful editorials makes it a vital resource for students, practitioners, and scientists alike. By offering exceptional access to influential publications, BLOOD continues to shape the future of hematology and enhance understanding of blood-related disorders, marking its vital role in advancing both basic and clinical research.